Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Ultragenyx Q3 revenue, FDA approvals, and big cost cuts boost profit outlook

Nov 3, 2026, 4:25 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong near-term profitability path from R&D cuts, plus revenue upside from BLAs and potential PRV monetization; reaffirmed guidance reduces uncertainty.

AI summary

What happened, with direct paths to the underlying reporting

Ultragenyx reported Q3 revenue of $173 million, led by CRYSVITA at $109 million and DOJOLVI at $30 million. FDA approved GENGLYCOS™ and FAYUVI™ BLAs in the quarter, with two PRVs under agreement for $413 million. The company also targets at least a 50% reduction in 2027 R&D spend versus 2025 and reaffirmed 2026 revenue and 2027 profitability guidance.

Q3 total revenue: $173 million; CRYSVITA: $109 million; DOJOLVI: $30 million.
GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in Q3.
Two Priority Review Vouchers (PRVs) under agreement for $413 million.
Headcount and expenses cuts target at least 50% reduction in 2027 R&D vs 2025; guidance reaffirmed.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Ultragenyx Q3 revenue, FDA approvals, and big cost cuts boost profit outlook

FDA Approval of Ultragenyx Gene Therapy Acts as Key Rare-Disease Catalyst

Ultragenyx late-stage failure weighs on RARE stock and pipeline

FDA approves Ultragenyx gene therapy, signaling potential upside for RARE

Ultragenyx's Patient-Focused Bootcamps Signal Growing Innovation in Rare Diseases